The changes from BL2 to BL1 containment can make a significant difference in enabling biopharmaceutical companies to deliver lifesaving or life-altering medicines quickly to the populations in need. Downgrading to BL1 would provide significant advantages for facility design, footprint, operations, cost savings, biosafety risk control, and more.
Publication
Viewing related articles
BioPhorum’s contribution to the CPHI Sustainability Report 2023.Â
Oct 2023 | News, Sustainability
BioPhorum Sustainability is helping industry’s transition to a low-carbon, circular future. Its vision is to improve patient health by providing biopharmaceuticals while respecting the planet and responsibly using its resources. A key element of this is communication and talking with those inside and outside industry to support and learn from them. As a Sustainability Partner at the CPHI event in Barcelona this October, BioPhorum was asked to...
How our value-driven FIT approach can increase your process reliability and patient safety
Oct 2023 | Drug Substance, News
No clear guidance is available on filter integrity testing (FIT) requirements in drug substance manufacturing. This paper aims to fill that gap with a risk-based, value-driven approach for FIT testing of sterilizing grade filters used to manufacture low bioburden drug substances.
How to use x-ray irradiation as an alternative sterilization modality to gammaÂ
Oct 2023 | Drug Substance, News
Single-use systems (SUS) are widely used throughout the pharmaceutical industry for manufacturing drug substance and drug product. After manufacture and packaging, many SUS are sterilized using gamma rays, typically emitted by radioactive Cobalt-60. However, industry demand for gamma irradiation (GI) is outpacing the available Cobalt-60 supply despite an increasing number of available nuclear reactor source sites. Also, the cost and enormous...
Introducing BioPhorum’s Closure PlaybookÂ
Oct 2023 | Drug Substance, News
Closing systems can promote innovation when designing new biologic facilities by minimizing the need for environmental control while providing better product protection. Designs based on closed systems operating within a ‘non-classified’ space can also be quicker and cheaper to build, cheaper to operate and more sustainable. However, while closed systems technology has been readily available for some time, facility design has not advanced at...
A unique safety data sheet for cell and gene therapies
Oct 2023 | Cell & Gene Therapy, News
With no established tool in the field, this guide contains industry best practices with aspirations of becoming a standard communication for workplace hazards unique to CGT biological materials and products.
Process analytical technology for CGTs – the big discussion
Sep 2023 | Cell & Gene Therapy, News
Our commentary summarizes the CGT industry views on PAT articulated during a virtual event and documents key takeaways on the benefits and barriers to PAT. It also notes the unique considerations for PAT in the context of CGTs and highlights some near-term options to help you accelerate these important therapies to patients before implementing PAT.
On your marks, get set, go! How to start your data governance project
Sep 2023 | News, Technology Strategy
Using the FAIR Principles (Findable, Accessible, Interoperable, and Reusable), our paper walks you through the first steps of building a structural framework so you can answer questions such as, can you find your data? When you find it, can you access it? Can it work with other systems?
Where to start with your biomanufacturing digital transformation
Sep 2023 | News, Technology Strategy
This BioPhorum paper will help you visualize the characteristics of a successful digital transformation and can be used to assess the organizational status of important attributes and identify gaps in need of attention. It can help strategic and operational teams focus on priority areas and improve communication between themselves, their sponsors, and external partners. This will lead to accelerated program or project timelines and increase the likelihood of successfully deploying new digital technologies.
The filling line of the future – industry needs for aseptic manufacture.
Sep 2023 | Fill Finish, News
Aimed at informing and assisting equipment providers in developing the right solution for the right place, this user vision, delivered by the Commercial Lines of the Future workstream, provides an overview of the future needs of the industry for aseptic manufacture. Representatives from more than 20 companies identified the important high-level requirements for aseptic manufacture for the next 10 years.